Slides
Page 1
1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Harnessing the Power of TIL Through Precision Cancer Biology in Non-Squamous Metastatic Non-Small-Cell Lung Cancer Supplemental Investor Presentation October 2026
Page 2
2 © 2026, Iovance Biotherapeutics, Inc. Tumor Harvest and TIL Expansion Reinfused TIL Recognize Tumor Cells TIL Activation and Tumor-Cell Death Antitumor Activity With Persistence TIL are isolated from the tumor, expanded to billions of cells, and reinfused. Reinfused TIL traffic to the tumor, recognize cancer cells, and bind to tumor antigens. Upon recognition, TIL are activated, releasing effector molecules to induce cell death. Infused lifileucel persist in the body and support polyclonal antitumor recognition and activity. Lifileucel TCR Peptide–HLA IFN-γ Perforin Granzymes Endogenous TIL Tumor Harvest Tumor Cells Tumor Cell Death What Makes a Tumor Responsive to TIL? Lifileucel treatment includes lymphodepletion prior to TIL infusion followed by IL - 2 infusion. Abbreviations: HLA, human leukocyte antigen; IFN - γ , interferon gamma; IL - 2, interleukin 2; TCR, T - cell receptor; TIL, tumor - infiltrating lymphocyte. 2 © 2026, Iovance Biotherapeutics, Inc.
Page 3
© 2026, Iovance Biotherapeutics, Inc. Unmasking the Tumor Microenvironment in NSCLC
Page 4
4 © 2026, Iovance Biotherapeutics, Inc. IOV-LUN-202 – Phase 2b Registration-Enabled Trial in NSCLC Phase 2 Multicenter Study of Lifileucel in Post-Anti-PD-1 Metastatic NSCLC [NCT04614103] Note: Unresectable or metastatic NSCLC with progression on or after prior anti-PD-1 treatment and chemotherapy, and KRAS inhibitor if KRAS mutation is present. Abbreviations: anti–PD-1, anti–programmed cell death protein 1; APAC, Asia-Pacific; CR, complete response; DCR, disease control rate; DOR, duration of response; IRC, independent review committee; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; TPS, tumor proportion score. IOV-LUN-202 is designed to enroll patients with advanced NSCLC post anti-PD-1 treatment Endpoints • Primary: ORR per RECIST v1.1 by IRC • Secondary: CR rate, DOR, DCR, PFS, OS, safety, and tolerability Patient Population Unresectable or metastatic NSCLC with progression on or after prior anti-PD-1 treatment and chemotherapy > 70 sites in U.S., Canada, Europe, APAC Cohort 1 < 1% or unknown TPS Cohort 2 ≥ 1% TPS Registrational Cohorts
Page 5
5 © 2026, Iovance Biotherapeutics, Inc. Demographics and Disease N = 84 Age, Years Median [range] 62 [26–78] ˂ 65 54 [64.3%] ≥ 65 30 [35.7%] Sex Male 50 [59.5%] Female 34 [40.5%] ECOG Status¹ 0 46 [54.8%] 1 37 [44.0%] 2 1 [1.2%] Smoking History Ever smoker 74 [88.1%] Never smoker 10 [11.9%] PD-L1 TPS² < 1% 32 [38.1%] 1 – 49% 33 [39.3%] ≥ 50% 16 [19.0%] Unknown 3 [3.6%] Histology Non-squamous 69 [82.1%] Squamous 15 [17.9%] Baseline SOD Median [range], mm 56.0 [10.0–258.4] Biomarkers, Prior Therapy, and Cell Dose N = 84 KRAS Status Mutant 35 [41.7%] Wild-type 44 [52.4%] Unknown 5 [6.0%] HER2 Status Mutant 4 [4.8%] Wild-type 71 [84.5%] Amplified 1 [1.2%] Unknown 8 [9.5%] Prior Therapy Exposure3 PD-[L]1 + chemotherapy 84 [100.0%] PD-[L]1 only 0 [0.0%] Chemotherapy only 0 [0.0%] Prior Lines 1 73 [86.9%] 2 11 [13.1%] Infused TVC, Billion Cells Mean 30.2 Median [range] 29.9 [10.0 – 60.0] 10 to < 20 21 [25.0%] 20 to < 40 39 [46.4%] ≥ 40 24 [28.6%] Baseline Characteristics Non-Squamous and Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy ¹ECOG measured pre-lymphodepletion. Ever smoker = former/current. Non-squamous: 68 adenocarcinoma + 1 LCNEC. ²Recorded site PD-L1 category; unknown retained. WT = no alteration detected; HER2 amplification is separate from mutation. ³Prior exposure at any time: PD-1/PD-L1 therapy and chemotherapy, concurrent or sequential; other therapies may also have been given. ⁴Same prior-KRAS-treatment rule: 88 patients at TVC ≥ 10B minus 4 G12C cases without documented prior sotorasib/adagrasib = 84. Abbreviations: ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene homolog; LCNEC, large cell neuroendocrine carcinoma; PD-L1, programmed death-ligand 1; PS, performance status; SOD, sum of diameters; TPS, tumor proportion score; TVC, total viable cells; WT, wild-type.
Page 6
6 © 2026, Iovance Biotherapeutics, Inc. Best Percentage Change From Baseline in Target Lesion by RECIST v1.1 -110 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 % Change From Baseline 1 2 3 4 5 6 7 8 9 10111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061 Patients [61/ 69 Total] Durability of Response1 15 Confirmed Responders + 2 Unconfirmed PRs* 59 51 57 61 38 55 43 60 42 45 49 44 56 47 53 58* 40* 0 6 12 18 24 30 36 42 48 54 Time [Months] since Lifileucel Infusion -24.2% Mean SOD 24.6% ORR [17/69] Best Response – Unselected Non-Squamous NSCLC Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy Data as of 14-Oct-2026 includes partial IRC; Non-squamous NSCLC, infused TVC ≥10 billion; KRAS prior-treatment sensitivity population [n=69]. ORR =17/69 [15 confirmed responses + 2 uPRs]. mSOD = −24.2% across 61 numerical values. Eight patients without numerical SOD remain in the ORR denominator. No imputation. 1Patient numbers match the waterfall. *Patients 40 (1143-104) and 58 (1207-103): Day 84 uPR; confirmation pending, no confirmed DOR assigned. Patient 40: −31%, Swimmer time is measured from infusion. Abbreviations: CR, complete response; mDOR, median duration of response; SOD, sum of diameters; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; TVC, total viable cells; uPR, unconfirmed partial response. Best Overall Response PD SD uPR* PR CR PR Onset uPR Onset Ongoing Progression / Off Study CR Onset
Page 7
© 2026, Iovance Biotherapeutics, Inc. A New Paradigm in Immuno-Oncology: Precision TIL in NSCLC
Page 8
8 © 2026, Iovance Biotherapeutics, Inc. Unmasking the Biology of TIL in NSCLC KRAS Wild-Type Tumors Permissive tumor microenvironment KRAS-Mutant Tumors Suppressive tumor microenvironment Increased IFN-γ IFN-γ TCR–HLA Recognition Lifileucel Non-Squamous NSCLC KRAS Wild-Type More Permissive Cytokine Milieu Active Tumor Killing Reduced IFN-γ IFN-γ TGF-β IL-10 Suppressive Cytokines Immune Suppression Weak Antigen Presentation Lifileucel TCR MDSC Treg Non-Squamous NSCLC KRAS Mutated More effective immune recognition, higher IFN-γ signaling, and active tumor killing in a permissive microenvironment. Reduced antigen presentation, lower IFN-gamma signaling, and increased TGF-β / IL-10 in a suppressive microenvironment limits TIL activity. Less Permissive Cytokine Milieu Limited Tumor Killing TCR Co-mutations and other factors may modify these states. Abbreviations: HLA, human leukocyte antigen; IFN-γ, interferon gamma; IL-10, interleukin 10; MDSC, myeloid-derived suppressor cell; NSCLC, non-small cell lung cancer; TCR, T-cell receptor; TGF-β, transforming growth factor beta; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cell.
Page 9
9 © 2026, Iovance Biotherapeutics, Inc. -34.5% Mean SOD Best Percentage Change From Baseline in Target Lesion by RECIST v1.1 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25* 26 27 28 Patients [28/ 30 Total] % Change From Baseline Durability of Response1 12 Confirmed Responders + 1 Unconfirmed PR* 26 21 28 15 23 16 27 18 17 24 20 22 25* 0 6 12 18 24 30 36 42 48 54 Time (Months) since Lifileucel Infusion 43.3% ORR [13/30] Best Response – KRAS Wild-Type in NSCLC Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy Data as of 14-Oct-2026 includes partial IRC; KRASWT non-squamous NSCLC, infused TVC ≥10 billion [n=30]. ORR = 13/30 [12 confirmed responses + 1 uPR]. Mean best SOD = −34.5% across 28 numerical values; 2 patients without numerical SOD remain in the ORR denominator. No imputation. 1Patient numbers match the waterfall. *Patient 25 [1207-103]: Day 84 uPR; confirmation pending; no confirmed DOR assigned. Swimmer lane time is measured from infusion. −30% alone does not establish a RECIST response. Abbreviations: CR, complete response; mDOR, median duration of response; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of diameters; uPR, unconfirmed partial response. Best Overall Response PD SD uPR* PR CR PR Onset uPR Onset Ongoing Progression / Off Study CR Onset
Page 10
10 © 2026, Iovance Biotherapeutics, Inc. Metrics KRAS Wild-Type KRAS Mutant Population [N = 69] 30 35 Confirmed ORR 40.0% [12/30] 8.6% [3/35] Confirmed + uPR ORR 43.3% [13/30] 11.4% [4/35] Mean SOD Change -34.5% -13.8% Median SOD Change -29.1% -11.3% KRAS Enriched Subgroup Comparison in NSCLC Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy Notes: Same all-comer eligibility basis as the waterfall slide [non-squamous NSCLC, infused TVC ≥10 billion]. Confirmed + uPR ORR includes one unconfirmed PR in KRASWT and one in KRAS mutation. Four patients with KRAS status recorded as Not Assessed are excluded from the side-by-side comparison table. Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; ORR, objective response rate; SOD, sum of diameters; TVC, total viable cells; uPR, unconfirmed partial response; WT, wild-type.
Page 11
11 © 2026, Iovance Biotherapeutics, Inc. Best Percentage Change From Baseline in Target Lesion by RECIST v1.1 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patients [24/ 25 Total] % Change From Baseline Durability of Response1 12 Confirmed Responders + 1 Unconfirmed PR* 22 17 24 11 19 12 23 14 13 20 16 18 21* 0 6 12 18 24 30 36 42 48 54 Time [Months] since Lifileucel Infusion 52.0% ORR [13/25] -40.4% Mean SOD Best Response – KRAS Wild-Type + HER2 Wild-Type in NSCLC Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy Data as of 14-Oct-2026 includes partial IRC; KRASWT + HER2WT non-squamous NSCLC, infused TVC ≥10 billion [n=25]. ORR = 13/25 [12 recorded confirmed responses + 1 uPR]. Mean best SOD = −40.4% across 24 numerical values; 1 patient without numerical SOD remains in the ORR denominator. No imputation. 1Swimmer lane times are approximate, measured from infusion. *Patient 21 [1207-103]: Day 84 uPR; confirmation pending. Abbreviations: CR, complete response; DOR, duration of response; HER2, human epidermal growth factor receptor 2; mDOR, median duration of response; SOD, sum of diameters; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of diameters; uPR, unconfirmed partial response; WT, wild-type. Best Overall Response PD SD uPR* PR CR PR Onset uPR Onset Ongoing Progression / Off Study CR Onset
Page 12
12 © 2026, Iovance Biotherapeutics, Inc. KRAS Enriched Subgroup Comparison in NSCLC Notes: Same all-comer eligibility basis as the waterfall slide [non-squamous NSCLC, infused TVC ≥10 billion, prior-treatment sensitivity adjustment]. Confirmed + uPR ORR includes one unconfirmed PR in KRASWT and the double gate, and one in KRAS mutant. Four KRAS-unassessed patients are excluded. KRASWT + HER2WT is a subset of KRASWT, not an independent cohort. Abbreviations: CR, complete response; DOR, duration of response; HER2, human epidermal growth factor receptor 2; mDOR, median duration of response; mSOD, mean sum of diameters; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of diameters; uPR, unconfirmed partial response; WT, wild-type. Metrics KRAS Wild-Type KRAS Wild-Type HER2 Wild-Type KRAS Mutant Population [N = 69] 30 25 35 Confirmed ORR 40.0% [12/30] 48% [12/25] 8.6% [3/35] Confirmed + uPR ORR 43.3% [13/30] 52.0% [13/25] 11.4% [4/35] Mean SOD Change -34.5% -40.4% -13.8% Median SOD Change -29.1% -38.1% -11.3% Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy
Page 13
13 © 2026, Iovance Biotherapeutics, Inc. Best Percentage Change From Baseline in Target Lesion by RECIST v1.1 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Patients [21 / 22 Total] % Change From Baseline Durability of Response1 12 Confirmed Responders + 1 Unconfirmed PR* 19 14 21 8 16 9 20 11 10 17 13 15 18* 0 6 12 18 24 30 36 42 48 54 Time [Months] since Lifileucel Infusion 59.1% ORR [13/22] -44.4% Mean SOD Best Response – KRAS Wild-Type + HER2 Wild-Type + Ever Smoker Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy Data as of 14-Oct-2026 includes partial IRC; KRASWT + HER2WT + ever-smoker non-squamous NSCLC, infused TVC ≥10 billion [n=22]. ORR = 13/22 [12 recorded confirmed responses + 1 uPR]. Mean best SOD = -44.4% across 21 numerical values; one patient without numerical SOD remains in the ORR denominator. No imputation. 2Swimmer lane times are approximate, measured from infusion. *Patient 18 [1207-103]: Day 84 uPR; confirmation pending; response. Abbreviations: CR, complete response; HER2, human epidermal growth factor receptor 2; mDOR, median duration of response; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of diameters; uPR, unconfirmed partial response; WT, wild-type. Best Overall Response PD SD uPR* PR CR PR Onset uPR Onset Ongoing Progression / Off Study CR Onset
Page 14
14 © 2026, Iovance Biotherapeutics, Inc. Metrics KRASWT KRASWT HER2WT KRASWT HER2WT Ever-Smoker KRASMUT HER2MUT Never Smoker Population [N = 69] 30 25 22 35 5 9 Confirmed ORR 40.0% [12/30] 48.0% [12/25] 54.5% [12/22] 8.6% [3/35] 0.0% [0/5] 0.0% [0/9] Confirmed + uPR ORR 43.3% [13/30] 52.0% [13/25] 59.1% [13/22] 11.4% [4/35] 0.0% [0/5] 0.0% [0/9] Mean SOD Change -34.5% -40.4% -44.4% -13.8% -2.5% -5.7% Median SOD Change -29.1% -38.1% -43.9% -11.3% +4.2% -8.8% KRAS Enriched Subgroup Comparison in NSCLC Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy Notes: N=69 non-squamous NSCLC, TVC ≥ 10B; Data as of 14-Oct-2026 includes partial IRC. Confirmed + uPR ORR includes 1 uPR in each WT/gated group; one in KRAS mutant. Never smokers include all 9, including 1 KRAS-unassessed patient. Ever-smoker = former/current. SOD summaries omit missing values; ORR does not. Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; ORR, objective response rate; SOD, sum of diameters; TVC, total viable cells; uPR, unconfirmed partial response; WT, wild-type.
Page 15
Spider Plot – KRAS Wild-Type + HER2 Wild-Type + Ever Smoker © 2026, Iovance Biotherapeutics, Inc. 15 1059-103 1092-102 1105-101 1180-103 1386-101 1207-103 1180-1011239-102 0 6 12 18 24 30 36 42 48 54 60 -120 -100 -80 -60 -40 -20 0 20 40 60 80 Months from First TIL Infusion % Change from Baseline in SOD [n=22] Best Overall Response [n=22] CR PR uPR SD PD Ongoing − Date as of 14-Oct-2026. Note: One patient has no plottable time-series data. Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy KRAS Wild-Type + HER2 Wild-Type + Ever Smoker
Page 16
16 © 2026, Iovance Biotherapeutics, Inc. Best Overall Response PD SD uPR* PR KRAS Mutant 11.4% ORR [4/35] Mean SOD: -13.8% -100 -50 0 50 1 3 7 12 14 18 21 24 27 31 35 40 42 49 52 % Change From Baseline Best Change in Target Lesion 1 2 3 5 7 8 12 13 14 16 18 20 21 23 24 25 27 28 31 33 35 36 40 41 42 48 49 50 52 57 Patients [30 / 35 Total] Durability of Response 3 Confirmed PRs + 1 Unconfirmed PR* 57 42 49 40* 0 6 12 18 24 30 36 42 48 Time [Months] since Lifileucel Infusion -100 -50 0 50 1 3 8 14 18 21 24 27 31 35 40 42 49 52 % Change From Baseline 1 2 3 7 8 12 14 16 18 20 21 23 24 25 27 28 31 33 35 36 40 41 42 48 49 50 52 57 Patients [28 / 33 Total] Durability of Response 3 Confirmed PRs + 1 Unconfirmed PR* 57 42 49 40* 0 6 12 18 24 30 36 42 48 Time [Months] since Lifileucel Infusion -100 -50 0 50 1 5 8 13 16 20 25 28 33 36 41 48 50 57 % Change From Baseline 1 3 5 7 8 12 13 14 16 18 20 24 25 27 28 31 33 35 36 40 41 42 48 49 50 52 57 Patients [27 / 31 Total] Durability of Response 3 Confirmed PRs + 1 Unconfirmed PR* 57 42 49 40* 0 6 12 18 24 30 36 42 48 Time [Months] since Lifileucel Infusion -100 -50 0 50 1 7 12 16 20 25 28 33 36 41 48 50 57 % Change From Baseline 1 3 7 8 12 14 16 18 20 24 25 27 28 31 33 35 36 40 41 42 48 49 50 52 57 Patients [25/ 29 Total] Durability of Response 3 Confirmed PRs + 1 Unconfirmed PR* 57 42 49 40* 0 6 12 18 24 30 36 42 48 Time [Months] since Lifileucel Infusion Response Visit uPR [Day 84] Ongoing Assessment End of Assessment KRAS Mutant + HER2 Wild-Type 12.1% ORR [4/33] Mean SOD: -15.2% KRAS Mutant + Ever-Smoker 12.9% ORR [4/31] Mean SOD: -15.7% Best Change in Target Lesion Best Change in Target Lesion Best Change in Target Lesion KRAS Mutant + HER2 Wild-Type + Ever-Smoker 13.8% ORR [4/29] Mean SOD: -17.5% Best Response– KRASMutant SubgroupComparisonin NSCLC Non-Squamous Metastatic NSCLC After Prior Anti-PD-1 Treatment and Chemotherapy Data as of 14-Oct-2026 includes partial IRC; Cohorts 1 and 2. NE patients remain in the ORR denominator. HER2WT includes “Not Detected”. Ever smoker = current/former. *Patient 40 (1143-104): −31% at Day 84, PI-reported uPR. Patient numbers match the reference slide; groups overlap. Lanes run from infusion to recorded assessment end or 13-Oct-2026 if ongoing. Abbreviations: HER2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene homolog; MUT, mutant; NE, not evaluable; ORR, objective response rate; SOD, sum of diameters; uPR, unconfirmed partial response; WT, wild-type.
Page 17
17 © 2026, Iovance Biotherapeutics, Inc. PosiTILity – Phase 2b Registration-Enabled Trial in NSCLC Phase 2 Multicenter Enriched Study of Lifileucel in Post-Anti-PD-1 and Chemotherapy Metastatic NSCLC [NCT04614103] Abbreviations: ALK, anaplastic lymphoma kinase; anti–PD-1, anti–programmed cell death protein 1; APAC, Asia-Pacific; CR, complete response; DCR, disease control rate; DOR, duration of response; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; IRC, independent review committee; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; ROS1, ROS proto-oncogene 1; TPS, tumor proportion score. Patient Population Unresectable or metastatic non-squamous NSCLC patients who are wild type for EGFR, ALK, ROS1, KRAS, and HER2 genomic alterations who have a current or prior tobacco smoking history with progression on or after prior anti-PD-1 treatment and chemotherapy > 70 sites in U.S., Canada, Europe, APAC Cohort 5 N = 80 Registrational LUN-202 Cohort 5 Endpoints Primary: ORR by RECIST v1.1with IRC Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability
Page 18
18 © 2026, Iovance Biotherapeutics, Inc. Pembrolizumab PD-1 blockade supports endogenous TIL activity Pembrolizumab + Lifileucel PD-1 blockade plus expanded autologous TIL Endogenous TIL Pembrolizumab Anti-PD-1 Suppressive Milieu ↑ IL-10 • TGF-β PD-1 Non-Squamous NSCLC KRAS Mutant Pembrolizumab Anti-PD-1 PD-1 Non-Squamous NSCLC KRAS Wild-Type Pembrolizumab Reinvigorates Endogenous TIL Releases PD-1 pathway inhibition Lifileucel Adds Increased Polyclonal TIL Population Broad neoantigen recognition and persistence Study Hypothesis: Can add-on lifileucel deepen responses and prolong disease control? Permissive Milieu ↓IL-10 • TGF-β • ↑IFN-γ Treg MDSC Lifileucel MDSC Active Tumor Killing TCR-Mediated Recognition Treg Complementary Biology in KRAS Enriched Frontline NSCLC Note: TIL regimen includes lymphodepletion and IL-2 support. Abbreviations: IFN-γ, interferon gamma; IL-2, interleukin 2; IL-10, interleukin 10; MDSC, myeloid-derived suppressor cell; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; TCR, T-cell receptor; TGF-β, transforming growth factor beta; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cell.
Page 19
19 © 2026, Iovance Biotherapeutics, Inc. Best Response – Phase 2 Study in Frontline Enriched NSCLC Pembrolizumab Plus Lifileucel in Anti-PD-1 and Chemotherapy-Naïve Frontline Non-Squamous Metastatic NSCLC Note: Non-squamous, KRASWT + ever-smokers: n=7. ORR = [1 CR + 5 PR]/7 = 85.7%. All responses were confirmed and by RECIST v1.1. NE remains in the denominator. Mean SOD = median lowest recorded percentage change from baseline. ORR includes 15/23 non-squamous patients with numeric change. All TVC levels included. Ever-smokers include former and current smokers. Exploratory subgroup analysis. Abbreviations: BOR, best overall response; CR, complete response; DOR, duration of response; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; mo, months; NE, not evaluable; NSCLC, non-small cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; SOD, sum of diameters; TVC, total viable cells. Frontline Non-Squamous NSCLC – KRAS Wild-Type + EGFR Wild-Type + Ever Smoker 64.3% ORR [9/14] Frontline Non-Squamous NSCLC – EGFR Wild-Type Only 85.7% ORR [6/7] Best Percentage Change from Baseline in Target Lesion by RECIST v1.1 -110 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 20 30 40 50 1057-309 1036-301 1036-315 1036-312 1003-306 1036-313 % Change from Baseline Patients [6 / 7 Total] Durability of Response: KRAS Wild-Type + Ever Smoker 6 Confirmed Responders: 1 CR + 5 PR 1036-313 1003-306 1036-315 1036-301 1057-309 1036-312 1056-305 0 6 12 18 24 30 36 42 48 Time [Months] since Lifileucel Infusion Non-Squamous KRAS Wild-Type + Ever Smoker Best Overall Response PD SD PR CR PR Onset Ongoing Progression / Off Study CR Onset
Page 20
20 © 2026, Iovance Biotherapeutics, Inc. Metric KRAS Wild-Type KRAS Mutant Population [N = 23] 10 6 Confirmed ORR 60.0% [6/10] 33.3% [2/6] Mean SOD Change -57.6% -4.5% Median SOD Change -69.7% -12.4% KRAS Enriched Subgroup Comparison in Frontline NSCLC Pembrolizumab Plus Lifileucel in Anti-PD-1 and Chemotherapy-Naïve Non-Squamous Metastatic NSCLC Note: Seven patients were not assessed for KRAS status. Abbreviations: KRAS, Kirsten rat sarcoma viral oncogene homolog; mNSCLC, metastatic non-small cell lung cancer; NSCLC, non-small cell lung cancer; ORR, objective response rate; SOD, sum of diameters; uPR, unconfirmed partial response.
Page 21
21 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Thank You.